PCRX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
176.7M
-8.2%
192.4M
+8.5%
177.4M
-9.9%
196.9M
+9.7%
179.5M
Cost of Revenue
37.2M
-15.7%
44.2M
+21.3%
36.4M
-9.6%
40.3M
+17.6%
34.3M
Gross Profit
139.4M
-5.9%
148.2M
+5.2%
141.0M
-10.0%
156.6M
+7.8%
145.2M
Operating Expenses
117.1M
-18.6%
144.0M
+7.4%
134.1M
-13.1%
154.2M
+11.1%
138.9M
R&D
26.7M
-11.8%
30.2M
+7.7%
28.1M
-25.0%
37.5M
+44.2%
26.0M
SG&A
83.8M
-8.7%
91.8M
-2.3%
93.9M
-7.5%
101.6M
+10.7%
91.8M
Operating Income
22.3M
+422.0%
4.3M
-38.2%
6.9M
+195.0%
2.3M
-63.2%
6.4M
EBITDA
40.9M
+55.9%
26.2M
-7.1%
28.2M
+19.2%
23.7M
-13.5%
27.4M
Net Income
28.5M
+513.0%
4.7M
+59.6%
2.9M
+78.1%
1.6M
-69.9%
5.4M
EPS (Basic)
$0.72
+500.0%
$0.12
+71.4%
$0.07
+75.0%
$0.04
-66.7%
$0.12
EPS (Diluted)
$0.70
+483.3%
$0.12
+71.4%
$0.07
+75.0%
$0.04
-66.7%
$0.12
Shares (Diluted)
40.8M
+1.3%
40.3M
-1.5%
40.9M
-6.4%
43.7M
-1.7%
44.5M
Pacira BioSciences (PCRX) — Financials